Recent works have shown that because of its important role in various aspects of the DDR, RAD52 also has potential as a therapeutic target in the treatment of hereditary breast, ovarian, and some other cancers (Feng et al., 2011; Nogueira et al., 2019; Gottifredi and Wiesmuller 2020). This evidence concerns the gene RAD52 and cancer.